Search PubMed⌕ Search

SEARCH · Search PubMed

Results for “Therapy development”

Search indexed PubMed citations on genomics, clinical trials, systematic reviews and public health. Explore titles, authors and supplied subject terms, then open the PubMed record.

Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.

At least 379 records · Page 21Linked to original sources
PubMed1981

[New developments in therapy and prophylaxis of viral hepatitis (author's transl)].

Acute viral hepatitis is in most of the cases a self-limited disease. Therefore, therapeutic procedures are concentrated upon chronic aggressive hepatitis. Thus far immunostimulation has proven to be not very effective, Antiviral therapy with interferon, poly I:C, vidarabine, or ribavirin seems to be more promising, but at present, immunosuppressive treatment is still the therapy of choice despite its obvious disadvantages. The shortcomings of therapy, accord the prophylaxis of viral hepatitis the greater chance. Against hepatitis A, passive immunisation can be achieved with ordinary gamma-globulin, whereas against hepatitis B, hyperimmunoglobulin (HBIg) has to be used. Active immunisation is presently possible against hepatitis A and B. In a few years, the necessary quantities of vaccine will be available to commence vaccination on a large scale. Some promising results are obtained in our endeavour against hepatitis non A non B, but an effective prophylaxis will not be available in the near future.

Antiviral Agents↗
PubMed1984

[Insulin receptor and postreceptor disorders: significance for the development and therapy of carbohydrate metabolic disorders].

The last decade has witnessed an explosion in our knowledge of the role of hormonal and neurotransmitter receptors in biological processes. The understanding gained of the interaction of insulin with its receptor has led to the recognition of receptor and postreceptor defects in various insulin resistant states. The purpose of this review is to summarize the actual state of knowledge concerning physiology and pathophysiology of insulin receptors and to relate these data to the role of insulin resistance in various pathological and non-physiological states. In addition, postreceptor abnormalities in a variety of disorders are reviewed. A number of possibilities for therapeutic intervention in insulin resistant states according to the specific underlying mechanism are described.

Autoantibodies↗
PubMed1982

[Hormones and tumor therapy: current clinical status and future developments in endocrine therapy of breast cancer].

Postoperative adjuvant hormone therapy and hormone therapy in disseminated breast cancer will be discussed systematically. The classical ablative and additive endocrine therapeutic measures--with the exception of ovarectomy and gestagen therapy--are increasingly being replaced by antagonists. Individual chapters discuss recent experience with combined hormone-radiotherapy or hormone-chemotherapy. In addition, a successful therapy scheme for the treatment of disseminated breast cancer will be presented.

Adrenal Cortex Hormones↗
PubMed1994

[Bronchial cancer--development, diagnosis, therapy, prognosis].

Lung cancer is the most frequent cause of death from cancer in men. In addition its prevalence among women is currently rapidly increasing. Main risk factors are smoking, exposure to asbestos and genetic factors. Current screening methods do not allow early detection and, hence, lung cancer is usually diagnosed at an advanced stage. The stage of the disease affects survival. In non-small cell lung cancer the probability of 5-year survival for patients is about 43% with stage I, 23% with stage II, 17% with stage IIIA and 2% with stage IIIB disease. Surgery plays a major role in patients with non-small cell lung cancer in stages I, II and maybe IIIA. In small cell lung cancer the probability of 5-year survival is about 10% for patients with limited disease and less than 1% for patients with extended disease. Although surgery plays a role in stage I to stage IIIA, chemotherapy remains the most important mode of therapy in small cell lung cancer. In stages I to IIIA, however, combined treatment modalities might improve outcome of the patients with small cell lung cancer.

Carcinoma, Bronchogenic↗